Table 3.
Blood pressure and heart rate responses compared between amiloride and placebo trials matched for time
| Placebo |
Amiloride |
RMANOVA |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n | BL | T50 | T100 | BL | TM50 | TM100 | Time | Drug | Int. | |
| HRmean, beats/min | 9 | 59 ± 6 | 71 ± 8 | 76 ± 8 | 62 ± 5 | 72 ± 7 | 76 ± 8 |
F = 33.43 ηP2 = 0.80 *P < 0.01 |
F = 0.68 ηP2 = 0.07 P = 0.43 |
F = 3.73 ηP2 = 0.31 *P = 0.04 |
| MAPmean, mmHg | 9 | 83 ± 7 | 91 ± 8 | 93 ± 8 | 82 ± 7 | 93 ± 11 | 94 ± 10 |
F = 38.0 ηP2 = 0.82 *P < 0.01 |
F = 0.06 ηP2 < 0.01 P = 0.81 |
F = 1.54 ηP2 = 0.16 P = 0.24 |
| SBPmean, mmHg | 9 | 110 ± 8 | 121 ± 11 | 124 ± 11 | 112 ± 8 | 125 ± 16 | 128 ± 16 |
F = 22.21 ηP2 = 0.73 *P < 0.01 |
F = 1.19 ηP2 = 0.13 P = 0.30 |
F = 1.42 ηP2 = 0.15 P = 0.27 |
| DBPmean, mmHg | 9 | 71 ± 7 | 78 ± 7 | 80 ± 7 | 70 ± 8 | 78 ± 10 | 80 ± 10 |
F = 44.32 ηP2 = 0.84 *P < 0.01 |
F < 0.01 ηP2 < 0.01 P = 0.94 |
F = 1.44 ηP2 = 0.15 P = 0.26 |
| BPI, mmHg·s/1,000 | 10 | 25.9 ± 13.2 | 49.4 ± 25.9 | 27.9 ± 13.6 | 41.8 ± 27.4 |
F = 14.11 ηP2 = 0.61 *P < 0.01 |
F = 2.72 ηP2 = 0.23 P = 0.13 |
F = 6.49 ηP2 = 0.49 *P = 0.03 |
||
| BPInorm, mmHg/kg | 10 | 8.1 ± 4.1 | 8.4 ± 4.3 | 8.2 ± 4.1 | 8.3 ± 4.1 |
F = 7.57 ηP2 = 0.45 *P = 0.02 |
F < 0.01 ηP2 < 0.01 P = 0.98 |
F = 1.06 ηP2 = 0.10 P = 0.32 |
||
Data are means ± SD for placebo and amiloride; n, number of participants. BL, baseline; BPI, blood pressure index; BPInorm, BPI normalized to the time-tension index; DBP, diastolic blood pressure; HR, heart rate; MAP, mean arterial pressure; ηp2, partial η squared; SBP, systolic blood pressure; T50, 50% of total exercise time within each trial; T100, 100% of total exercise time within each trial; TM50, time matched for 50% of total exercise time in the placebo trial; TM100, time matched for 100% of the total exercise time in the placebo trial. *Statistically significant P value.